These in vitro observations and the here described inhibitory effects of rolipram on Smad signalling and CTGF/transgelin expression in lung epithelial cells underline that PDE-4 inhibitors may offer a novel therapeutic strategy for respiratory diseases and could possibly also provide a therapeutic option for very preterm infants with BPD. The gene discussed is TAGLN; the disease is bronchopulmonary dysplasia.